Investigating glatiramer acetate for relapsing–remitting multiple sclerosis at the double dose—is more better?

被引：0
|
作者：
Peter A Calabresi
机构：
[1] PA Calabresi is Associate Professor of Neurology and Director of the Johns Hopkins Multiple Sclerosis Center,
[2] Baltimore,undefined
[3] MD,undefined
[4] USA.,undefined
来源：
Nature Clinical Practice Neurology | 2007年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：540 / 541
页数：1
相关论文
共 50 条
  • [41] Fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis - ASSESS study results
    Cree, B. A.
    Goldman, M. D.
    Corboy, J. R.
    Singer, B.
    Fox, E.
    Arnold, D. L.
    Ford, C.
    Weinstock-Guttman, B.
    Bar-or, A.
    Mientus, S.
    Sienkiewicz, D.
    Zhang, Y.
    Karan, R.
    Tenenbaum, N.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 163 - 163
  • [42] A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate
    Moreau, T.
    Brudon, F.
    Debouverie, M.
    Heinzlef, O.
    Lebrun-Frenay, C.
    Gury, C.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S99 - S99
  • [43] Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Khan, O
    Shen, YM
    Caon, C
    Bao, F
    Ching, W
    Reznar, M
    Buccheister, A
    Hu, JN
    Latif, Z
    Tselis, A
    Lisak, R
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (06) : 646 - 651
  • [44] NATALIZUMAB VERSUS GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
    Sultanov, M.
    Almadiyeva, A.
    Absattarova, K.
    Semenova, Y.
    [J]. VALUE IN HEALTH, 2018, 21 : S331 - S331
  • [45] Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis
    Crescenzo, F.
    Marastoni, D.
    Zuco, C.
    Pitteri, M.
    Magliozzi, R.
    Monaco, S.
    Calabrese, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 694
  • [46] Characteristics of Switching from Interferon beta to Glatiramer Acetate in Non Respondent Relapsing Remitting Multiple Sclerosis
    Oreja-Guevara, Celia
    Bermejo-Velasco, Pedro
    Miralles, Ambrosio
    Diez-Tejedor, Exuperio
    [J]. NEUROLOGY, 2010, 74 (09) : A550 - A550
  • [47] Anaphylactic Reaction after Injection of Glatiramer Acetate (Copaxone®) in Patients with Relapsing-Remitting Multiple Sclerosis
    Baumgartner, Annette
    Stich, Oliver
    Rauer, Sebastian
    [J]. EUROPEAN NEUROLOGY, 2011, 66 (06) : 368 - 370
  • [48] Glatiramer Acetate (Copaxone®) in the Treatment of Relapsing/Remitting Cerebrospinal Multiple Sclerosis - Clinical Efficacy and Safety Profile
    Stourac, P.
    Praksova, P.
    Kontrova, I.
    Hladikova, M.
    Okacova, I.
    Benesova, Y.
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 447 - 454
  • [49] Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis
    Schipper, Hyman M.
    Arnold, Douglas
    Grand'Maison, Francois
    Melmed, Calvin
    Moore, Fraser
    Levental, Mark
    Su, Haixiang
    Constantin, Michel
    Stril, Jean-Louis
    Godin, Jean
    [J]. CLINICAL NEUROPHARMACOLOGY, 2015, 38 (04) : 127 - 131
  • [50] Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment
    Caporro, Matteo
    Disanto, Giulio
    Gobbi, Claudio
    Zecca, Chiara
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1 - 12
12345